233 related articles for article (PubMed ID: 28320945)
1. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
Li C; Singh B; Graves-Deal R; Ma H; Starchenko A; Fry WH; Lu Y; Wang Y; Bogatcheva G; Khan MP; Milne GL; Zhao S; Ayers GD; Li N; Hu H; Washington MK; Yeatman TJ; McDonald OG; Liu Q; Coffey RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2852-E2861. PubMed ID: 28320945
[TBL] [Abstract][Full Text] [Related]
2. Broad-spectrum receptor tyrosine kinase inhibitors overcome
Graves-Deal R; Bogatcheva G; Rehman S; Lu Y; Higginbotham JN; Singh B
Oncotarget; 2019 Feb; 10(13):1320-1333. PubMed ID: 30863492
[TBL] [Abstract][Full Text] [Related]
3. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
4. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
5. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
6. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
7. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
Jones VT; Graves-Deal R; Cao Z; Bogatcheva G; Ramirez MA; Harmych SJ; Higginbotham JN; Sharma V; Damalanka VC; Wahoski CC; Joshi N; Irudayam MJ; Roland JT; Ayers GD; Liu Q; Coffey RJ; Janetka JW; Singh B
Cell Mol Life Sci; 2024 Jan; 81(1):28. PubMed ID: 38212428
[TBL] [Abstract][Full Text] [Related]
9. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
[TBL] [Abstract][Full Text] [Related]
10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
11. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
Lev A; Deihimi S; Shagisultanova E; Xiu J; Lulla AR; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2017 Sep; 18(9):694-704. PubMed ID: 28886275
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
14. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
15. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
[TBL] [Abstract][Full Text] [Related]
16. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
17. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
[TBL] [Abstract][Full Text] [Related]
19.
Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
[TBL] [Abstract][Full Text] [Related]
20. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
